Posted by Michael Wonder on 11 Apr 2019
Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis
11 April 2019 - Document open to public comment until 1 May 2019.
BOSTON, April 11, 2019 - The Institute for Clinical and Economic Review (ICER) has posted a Draft Scoping Document outlining a planned review of the comparative clinical effectiveness and value of treatments for rheumatoid arthritis.
ICER's assessment will incorporate data that has emerged since ICER's initial review of RA therapies in 2017. In addition to re-assessing each of the therapies included in that previous report, ICER will evaluate the approved biosimilar Inflectra (infliximab-dyyb, Pfizer and Celltrion), as well as upadacitinib (AbbVie), which is currently under review by the FDA with an expected decision around August 2019.
